Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913434 | 1.00 | MMP12 (0.39) | MMP12NPC1MAPTMMP2MMP3 | |
| SCHEMBL12787299 | 0.87 | TSHR (0.38) | NPC1TSHR | |
| SCHEMBL10562143 | 0.85 | MAPT (0.36) | MMP12MAPTMMP2MMP3MMP9 | |
| SCHEMBL10433826 | 0.85 | MAPT (0.36) | MMP12MAPTMMP2MMP3MMP9 | |
| SCHEMBL25175870 | 0.83 | MAPT (0.38) | MMP12MAPTMMP2MMP3HTT | |
| SCHEMBL8952823 | 0.83 | MAPT (0.38) | MMP12MAPTMMP2MMP3HTT | |
| SCHEMBL8952810 | 0.83 | MAPT (0.38) | MMP12MAPTMMP2MMP3HTT | |
| SCHEMBL9828488 | 0.83 | MAPT (0.35) | MMP12MAPTMMP2MMP3HTT | |
| SCHEMBL10433967 | 0.83 | MAPT (0.35) | MMP12MAPTMMP2MMP3HTT | |
| SCHEMBL12268284 | 0.83 | MAPT (0.39) | MMP12MAPTMMP2MMP3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065920-A1 | PROCESS FOR PREPARING PENTANOIC DIACID DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2223909-A1 | Process for preparing pentanoic diacid derivatives | Ratiopharm GmbH (DE) | 2010-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065920-A1 | PROCESS FOR PREPARING PENTANOIC DIACID DERIVATIVES | HMGCR, DPYD, FDPS | MMP12 3662/4885NPC1 334/4885MAPT 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.